Resources

In part 4 of this Exclusive Interview, Dr. Francine Kaufman talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the making of and effectiveness of the 670G sensors.

In part 5 of this Exclusive Interview, Dr. Francine Kaufman talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about Medtronic's continued work on products for both type 1 and type 2 patients.

In part 6, the conclusion of this Exclusive Interview, Dr. Francine Kaufman talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about maintaining a position in the market and the importance of customer service.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of diabetic medications indicated only for the treatment of type 2 diabetes. In conjunction with exercise and a healthy diet, they can improve glycemic control. They have been studied alone and with other medications including metformin, sulfonylureas, nizagara 100, pioglitazone, and …

Global healthcare company Novo Nordisk, renewed its partnership with Team Novo Nordisk for an additional two years, extending the company’s commitment to the world’s first all-diabetes professional cycling team to a total of seven years.

In the conclusion of this Exclusive Interview, Drs. Sood and Messer talk with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about their individual diet philosophies and behavior modification.

In this week's Homerun Slides, results of the HOPE trial and LIFE Study, and the main mediators that contribute to chronic kidney disease.

Therapeutic approaches to the dyslipidemia of insulin resistance and type 2 diabetes mellitus -- Key points: The rationale for treating the diabetic dyslipidemia is clear, it is associated with significantly increased risk of cardiovascular events.Weight loss, exercise, and diet modifications are key to successful treatment of all of the lipid abnormalities in patients with T2DM. Statins are the mainstay of therapy—they lower LDL cholesterol up to 50%, lower triglycerides about 15–25%, and have minimal effects of HDL cholesterol levels.

New study finds lower occurrence of heart failure in older people with type 2.

Real-time monitoring produces significant long-term improvement in HbA1c.